BioSkryb ResolveSeq MRD

BioSkryb has launched ResolveSeq MRD, a service for classification and characterization of the minimum residual disease cells in hematologic malignancies. ResolveSeq MRD pairs single-cell genome and transcriptome characterization and integrates with flow cytometry protocols. It provides clonal evolution mapping and risk stratification for each subclone, the company said.